Last updated: September 26, 2026
VIDEX, the branded formulation of didanosine, is a legacy HIV nucleoside reverse-transcriptase inhibitor that has lost commercial relevance. Bristol-Myers Squibb developed and marketed VIDEX after U.S. approval in 1991. Generic didanosine, declining use because of toxicity and resistance concerns, and the shift toward simpler fixed-dose antiretroviral regimens reduced the product to a low-value, largely discontinued market. VIDEX does not have a meaningful current revenue trajectory, active exclusivity position, or biosimilar threat. Its remaining commercial value is concentrated in limited generic supply and historical intellectual property.
What is VIDEX and what disease does it treat?
VIDEX contains didanosine, an antiretroviral used with other agents to treat HIV-1 infection. Didanosine inhibits HIV reverse transcriptase after intracellular conversion to its active triphosphate form.
The product was marketed in several dosage forms:
| Product |
Active ingredient |
Principal use |
Commercial status |
| VIDEX chewable or buffered tablets |
Didanosine |
HIV-1 treatment |
Legacy product |
| VIDEX pediatric powder |
Didanosine |
Pediatric HIV treatment |
Legacy product |
| VIDEX EC delayed-release capsules |
Didanosine |
HIV-1 treatment |
Legacy product, generally no longer commercially important |
VIDEX was an early antiretroviral product. It gained adoption before the widespread availability of modern combination therapies, integrase inhibitors, and once-daily fixed-dose regimens.
The product had material safety limitations. FDA labeling identified risks including pancreatitis, peripheral neuropathy, lactic acidosis, hepatic toxicity, retinal changes, and serious drug interactions. These risks constrained long-term use and weakened its position against newer HIV therapies (U.S. Food and Drug Administration, 2010).
How has the VIDEX market changed?
The VIDEX market moved through four identifiable stages.
| Period |
Market condition |
Effect on VIDEX |
| 1991 to mid-1990s |
Early antiretroviral market with limited treatment options |
Rapid clinical adoption |
| Late 1990s to early 2000s |
Combination therapy expanded; protease inhibitors and additional NRTIs gained share |
VIDEX remained relevant but became one component of multidrug therapy |
| Mid-2000s to 2010s |
Safer, better tolerated and more convenient regimens displaced older NRTIs |
Sharp demand decline |
| 2020s |
Generic and legacy-use market only |
Minimal branded commercial value |
Didanosine’s clinical role declined for several reasons:
- It required careful administration and, in some formulations, fasting conditions.
- Toxicity was more consequential than with many newer agents.
- Resistance limited its use after treatment failure.
- Once-daily and single-tablet regimens offered better adherence.
- Modern treatment guidelines prioritized integrase inhibitor-based combinations over older nucleoside backbones.
- The HIV market shifted from individual legacy products to branded combination products and complete regimens.
The World Health Organization no longer treats didanosine as a core component of preferred first-line HIV treatment. Its role in contemporary HIV care is restricted and generally associated with historical or exceptional treatment situations (World Health Organization, 2021).
What is the financial trajectory of VIDEX?
VIDEX had its highest commercial value during the period before modern antiretroviral combinations became dominant. Its financial trajectory is best described as a rise-and-decline curve rather than a continuing growth asset.
Early growth
Following U.S. approval in 1991, VIDEX benefited from:
- A large unmet need for additional HIV therapies.
- Limited competition among nucleoside reverse-transcriptase inhibitors.
- Use in combination regimens.
- Expansion of HIV diagnosis and treatment.
- Institutional and government purchasing.
Maturity and erosion
By the late 1990s and early 2000s, VIDEX faced competitive erosion from products with more favorable dosing, tolerability, and resistance profiles. Bristol-Myers Squibb’s HIV portfolio increasingly depended on products such as SUSTIVA and REYATAZ, while the broader market moved toward complete combination regimens.
Decline and discontinuation
VIDEX became commercially marginal as:
- Generic didanosine entered or became available in relevant markets.
- HIV guidelines reduced reliance on didanosine.
- Physicians shifted away from older NRTIs with serious mitochondrial, pancreatic, neurologic, or metabolic risks.
- The value of single-agent or standalone antiretroviral brands declined relative to combination products.
- Product discontinuation or limited distribution reduced brand visibility.
Bristol-Myers Squibb did not maintain a durable, separately reported revenue line for VIDEX in its later public financial reporting. The company’s disclosures generally grouped HIV products into broader portfolio categories or identified larger assets individually. As a result, a reliable current VIDEX revenue figure cannot be inferred from company reports. The commercial conclusion is clear: VIDEX is no longer a material contributor to Bristol-Myers Squibb revenue.
When did VIDEX lose exclusivity?
VIDEX’s original U.S. product exclusivity expired years ago. The product’s principal composition and early formulation protections were filed in the 1980s and early 1990s, placing their ordinary patent terms in the 2000s or earlier, subject to patent-term adjustments, extensions, and jurisdiction-specific rules.
The delayed-release VIDEX EC formulation received later protection than the original VIDEX product. Those formulation rights also have no practical current exclusivity value. Generic didanosine products have been available in the United States and other markets, although supply and commercial availability have varied.
| Exclusivity category |
VIDEX position |
| New chemical entity exclusivity |
Expired |
| Original composition patents |
Expired |
| Early tablet and powder formulation patents |
Expired |
| VIDEX EC delayed-release formulation rights |
Expired or commercially exhausted |
| Pediatric exclusivity |
Historical and expired |
| Current branded exclusivity |
None of material commercial significance |
| Biosimilar exclusivity |
Not applicable |
The product is a small molecule, not a biologic. Biosimilar competition therefore does not apply. The relevant competitive risk is generic substitution and therapeutic displacement by newer antiretroviral regimens.
What is the Orange Book status of VIDEX?
VIDEX’s Orange Book relevance is historical. The Orange Book identifies approved drug products and patent information submitted by sponsors, but an Orange Book listing does not itself preserve commercial exclusivity after patent expiration.
Current commercial analysis should distinguish among:
- Historical VIDEX patents.
- Any product listings that remain administratively visible.
- Expired patent claims.
- Discontinued brand presentations.
- Approved generic didanosine products.
No active VIDEX patent position is known to create a meaningful barrier to generic launch. The principal commercial question is not whether a generic can legally enter, but whether sufficient demand and supply economics justify continued production.
What patents protected VIDEX?
VIDEX protection historically included several layers.
Composition and active-ingredient protection
The earliest protection covered didanosine and related chemical subject matter. Those rights were filed well before the product’s 1991 approval and have expired.
Tablet and powder formulations
Buffered tablets and pediatric powder presentations required formulation work to improve stability, dispersibility, and administration. These protections were narrower than the active-ingredient claims and were vulnerable to expiration and design-around strategies.
VIDEX EC delayed-release capsules
The enteric or delayed-release formulation was designed to reduce degradation in the stomach and improve administration. Formulation patents could delay generic competition if they covered the specific release profile, coating, capsule structure, or manufacturing process. Those rights no longer support a significant current exclusivity position.
Manufacturing and process rights
Process patents may have covered preparation, granulation, coating, or release-control techniques. Such patents would have had limited residual value after product and formulation patent expiration because manufacturers could use alternative processes.
Were there Paragraph IV challenges to VIDEX?
VIDEX was exposed to the same generic challenge framework as other small-molecule drugs listed in the Orange Book. A generic applicant could file an Abbreviated New Drug Application with a Paragraph IV certification asserting that listed patents were invalid, unenforceable, or not infringed.
The commercially relevant period for Paragraph IV activity was the late 1990s and 2000s, particularly as generic manufacturers evaluated didanosine tablets, powders, and delayed-release capsules. Any historic Paragraph IV litigation would have centered on:
- Validity of formulation patents.
- Scope of delayed-release claims.
- Infringement by generic release profiles.
- Patent-term calculations.
- FDA approval timing.
There is no current Paragraph IV event that materially changes the VIDEX market outlook. The product’s principal barriers are now demand, clinical relevance, manufacturing economics, and procurement rather than enforceable patent rights.
Which companies challenged or competed with VIDEX?
VIDEX competed against both branded antiretrovirals and generic didanosine.
Branded HIV competitors
The most important competitive pressure came from other NRTIs and later from complete antiretroviral combinations. Relevant historical competitors included:
- ZERIT, containing stavudine.
- RETROVIR, containing zidovudine.
- EPIVIR, containing lamivudine.
- ZIAGEN, containing abacavir.
- VIREAD, containing tenofovir disoproxil fumarate.
- SUSTIVA, containing efavirenz.
- REYATAZ, containing atazanavir.
- Fixed-dose combination products containing multiple NRTIs or integrase inhibitors.
The competitive advantage shifted toward lower toxicity, once-daily administration, fewer food restrictions, stronger resistance profiles, and complete single-tablet regimens.
Generic competitors
Generic didanosine manufacturers competed primarily on price, supply continuity, and regulatory approval rather than brand differentiation. The generic market is small because modern HIV guidelines have sharply reduced didanosine use.
What regulatory status does VIDEX have?
VIDEX was approved by the FDA for use with other antiretroviral agents in HIV-1 infection. Its regulatory position is now legacy-oriented.
| Regulatory issue |
Status |
| FDA original approval |
1991 |
| Active new chemical entity exclusivity |
Expired |
| Current treatment guideline position |
Limited and generally unfavorable |
| Generic pathway |
ANDA pathway applicable |
| Biosimilar pathway |
Not applicable |
| Current branded growth opportunity |
None evident |
| Primary regulatory risk |
Discontinuation, supply reduction, or limited availability |
Discontinuation status can differ by dosage form and country. A product may be discontinued commercially while the underlying active ingredient remains approved or available through generic suppliers. FDA discontinuation records must therefore be read by specific presentation rather than treated as a single status for all didanosine products.
How strong is the VIDEX patent estate?
The current VIDEX patent estate is weak from a commercial-defense perspective.
| Patent-strength factor |
Assessment |
| Core active-ingredient protection |
Expired |
| Formulation protection |
Expired or no longer commercially decisive |
| Method-of-use protection |
Expired or clinically obsolete |
| Manufacturing protection |
Potentially narrow and design-aroundable |
| Orange Book leverage |
Low |
| Generic entry barrier |
Low |
| Litigation leverage |
Low |
| Lifecycle-management potential |
Minimal |
Historical patent strength may have been meaningful when VIDEX EC delayed-release technology was introduced. The present value of those rights is limited because generic manufacturers can rely on expired patents, alternative formulations, or different manufacturing processes.
What generic launch risks exist for VIDEX?
Generic launch risk is high in legal terms but muted in financial terms.
A generic manufacturer can face several practical obstacles:
- Small and declining patient population.
- Low reimbursement value.
- Limited physician demand.
- Procurement volatility.
- Manufacturing complexity for delayed-release capsules.
- Inventory and pharmacovigilance costs.
- Competition from more clinically favored therapies.
These factors can discourage new entrants even when patent barriers are absent. The result is a thin market in which generic availability may be intermittent without creating meaningful pricing power for the branded product.
How does VIDEX compare with modern HIV drugs?
| Attribute |
VIDEX |
Modern integrase inhibitor-based regimens |
| Drug class |
NRTI |
Often integrase inhibitor plus NRTI backbone |
| Dosing convenience |
Less favorable |
Commonly once daily |
| Toxicity profile |
Significant historical concerns |
Generally more favorable |
| Resistance position |
Weak relative to current standards |
Stronger in first-line use |
| Formulation |
Multiple legacy presentations |
Frequently fixed-dose tablets |
| Guideline role |
Limited |
Core treatment option |
| Patent value |
Expired |
May remain material for newer products |
| Commercial outlook |
Declining or discontinued |
Active, with branded and generic competition varying by product |
VIDEX cannot compete directly on convenience or clinical positioning. Its remaining relevance is primarily historical, generic, or restricted to settings where treatment options are constrained.
What revenue exposure remains for Bristol-Myers Squibb?
Bristol-Myers Squibb has no meaningful current revenue exposure to VIDEX. The company’s financial risk from the product is more likely to involve:
- Product discontinuation costs.
- Residual manufacturing obligations.
- Regulatory maintenance expenses.
- Inventory and supply-chain closeout.
- Historical liability or litigation exposure.
VIDEX should not be modeled as a growth product, a patent-expiration event with material revenue impact, or a major contributor to Bristol-Myers Squibb’s HIV portfolio. Any residual sales would be immaterial relative to the company’s current oncology, immunology, cardiovascular, and other specialty pharmaceutical franchises.
What licensing deals and settlements affected VIDEX?
VIDEX’s historical commercial development occurred within Bristol-Myers Squibb’s HIV franchise. No current licensing deal is known to create material value for VIDEX.
Patent settlements, if any, would have been relevant only during the product’s active exclusivity period. Such settlements could have established delayed generic entry dates or other launch conditions. They no longer alter the product’s strategic position because the branded product has already lost its primary commercial protections.
Key Takeaways
- VIDEX is the legacy didanosine brand developed and marketed by Bristol-Myers Squibb.
- FDA approval occurred in 1991.
- The product’s commercial peak occurred before modern combination and integrase inhibitor-based HIV therapy became standard.
- Toxicity, dosing limitations, resistance concerns, and therapeutic displacement drove long-term decline.
- Core composition and formulation patents have expired.
- VIDEX has no meaningful current patent exclusivity or biosimilar risk.
- Generic didanosine can face low-demand and supply-economics barriers despite limited legal barriers.
- Bristol-Myers Squibb does not report VIDEX as a material current revenue contributor.
- The product’s financial trajectory is effectively complete, with only residual generic or legacy-market activity.
FAQs
Is VIDEX still available in the United States?
Brand availability is limited and may vary by dosage form. Generic didanosine availability can also vary because demand is low and manufacturers may discontinue or restrict supply.
Is didanosine still recommended for first-line HIV treatment?
No. Contemporary HIV guidelines generally favor integrase inhibitor-based regimens and better-tolerated nucleoside backbones. Didanosine has a limited clinical role.
Can a generic company launch didanosine without a patent license?
Expired patents do not require a license. A generic applicant must still satisfy FDA approval requirements and address any remaining listed patents or regulatory exclusivities.
Does VIDEX have biosimilar competition?
No. Didanosine is a chemically synthesized small molecule. Generic competition, not biosimilar competition, is the relevant framework.
What is the investment case for VIDEX?
There is no evident standalone investment case based on revenue growth, patent protection, or strategic lifecycle management. Any residual value is limited to niche generic supply or legacy portfolio management.
References
-
Bristol-Myers Squibb Company. (2000-2023). Annual reports and Form 10-K filings. Bristol-Myers Squibb.
-
U.S. Food and Drug Administration. (2010). VIDEX and VIDEX EC prescribing information. U.S. Department of Health and Human Services.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. U.S. Department of Health and Human Services.
-
World Health Organization. (2021). Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: Recommendations for a public health approach. World Health Organization.
-
U.S. Department of Health and Human Services. (2024). Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. ClinicalInfo.HIV.gov.
